Cardiac shock wave therapy improves angina symptoms

Cardiac shock wave therapy improves angina symptoms

(HealthDay) -- Cardiac shock wave therapy (CSWT) can significantly improve symptoms, ischemic threshold during exercise, and specific quality-of-life parameters for patients with chronic refractory angina pectoris, according to a study published online March 23 in Cardiovascular Therapeutics.

To investigate whether CSWT can relieve the symptoms of chronic refractory angina pectoris, Jean-Paul Schmid, M.D., of the Bern University Hospital in Switzerland, and colleagues conducted a prospective, randomized, placebo-controlled study involving 21 patients with chronic refractory angina pectoris and evidence of inducible myocardial ischemia during MIBI single-photon emission computed tomography imaging. Eleven patients received nine sessions of CSWT (200 shots/spot, energy intensity of 0.09 mJ/mm²) over three months, and 10 controls received an acoustic simulation without energy application.

The researchers found that nine of 11 CSWT-treated patients experienced statistically significant symptom improvement, measured by cardiopulmonary stress testing, compared with two of 10 placebo-treated patients. Physical functioning, general health perception, and vitality items on the Short Form-36 questionnaire were significantly improved in CSWT-treated patients, compared with no improvement in placebo-treated patients.

"This prospective, randomized study shows that CWST reduces clinical symptoms and objective signs of . CSWT therefore emerges as a new non-invasive technique for treatment of refractory angina pectoris in patients with advanced coronary artery disease," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Time to take notice and tackle heart failure

12 hours ago

Experts have sounded a call to action for policy makers at local, national, and international levels to promote heart failure prevention, improve heart failure awareness among healthcare professionals, ensure ...

Hopes dashed for an agent to prevent reperfusion injury

15 hours ago

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective ...

User comments